jake,
The stock price and its reactions to news are all part of the method of financing for this company. All good news is shorted by the "investor" that gets discounted shares to cover with when the company needs to raise cash. Pretty simple and all data points to that action imo. Unfortunately it took alot of good news and shorting to get the latest financing done (1 years worth?). Not alot of interest in this stock. The board is controlled by PIPE financiers/penny stock operators. Its not a good recipe for bringing a drug to market. Bavi is looking to be more of an adjuvant drug which is a tough sell against standard of care and other drugs trying to be frontrunners. As exciting as Bavi is its not going to post efficacy that sells itself...at least not in Phase 1 studies and likely not in limited Phase II studies either. Put that challenge in the hands of this board/management that knows PIPE financing and some science but not a whole lot about biotech deal making, marketing and bringing a drug to market.
ON another topic: It seems funny to me to believe an analyst report on this way uner a buck stock from little ol Rodman and Renshaw is going to do a lot for the stock price. Not with the huge float and "investor" (see above) motivations. To stave off another PIPE once again the company needs a substantial partner deal by next summer and its getting obvious (maybe even to BOT) that that is getting very speculative as the clock ticks.
There is really only one type of good news... a partner deal. And not some bs "deal with god." I'll buy in at a much higher price on legitimate partner news. The risk became too high starting late last year and I require the insurance(assuarance).
Wish you the best and hope I'm forced to buy back albeit at a likely much higher price than where it stands today.
News 
Market Data 
Discover 
